Clinical Trials Logo

Filter by:
NCT ID: NCT03327597 Recruiting - Clinical trials for Monoclonal Gammopathy of Undetermined Significance

Iceland Screens, Treats or Prevents Multiple Myeloma

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.

NCT ID: NCT03272516 Recruiting - Depression, Anxiety Clinical Trials

Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients

Start date: September 12, 2017
Phase: N/A
Study type: Interventional

This study is done to evaluate the effects of Mindfulness Based Cognitive Therapy (MBCT) for primary care patients that have mild to moderate symptoms of depression and anxiety. Half of the study participants will receive treatment as usual (TAU), and the other half will receive TAU plus MBCT. The investigators will be comparing changes in symptoms of depression and anxiety between the groups, and hypothesize that the TAU plus MBCT group will have significantly lower symptoms of depression and anxiety compared to TAU group post-intervention

NCT ID: NCT03176732 Recruiting - Hypertension Clinical Trials

Mechanisms for Individual Differences in Hypertension in Obstructive Sleep

Start date: June 6, 2017
Phase: N/A
Study type: Observational

Hypertension is a common consequence of obstructive sleep apnea (OSA). However, not all individuals with OSA have hypertension and there are major individual differences in blood pressure response to positive airway pressure treatment of OSA. This project is focused on determining the basis of these individual differences in blood pressure response to OSA and will evaluate the possible underlying reasons for these differences. The results will help clinicians to know whether or not to expect a reduction in blood pressure (BP) to OSA treatment in a given patient and thereby personalize patient management.

NCT ID: NCT03174002 Recruiting - Clinical trials for Hypoxemic Respiratory Failure

Handling Oxygenation Targets in the Intensive Care Unit

Start date: June 19, 2017
Phase: Phase 4
Study type: Interventional

Handling oxygenation targets (HOT) is standard of care in the intensive care unit (ICU), however the quality and quantity of evidence is low and potential harm has been reported. The aim of the HOT-ICU trial is to assess the overall benefits and harms of two levels of oxygenation targets in adult critically ill patients with acute hypoxaemic respiratory failure in the ICU.

NCT ID: NCT02900378 Recruiting - Clinical trials for Chronic Heart Failure With Reduced Ejection Fraction

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Start date: December 20, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, actively controlled, double-blind study is to demonstrate the superiority of sacubitril/valsartan over enalapril in increasing non-sedentary physical activity chronic heart failure patients with reduced ejection fraction. Physical activity will be continuously measured by means of a wrist-worn accelerometry device from 2 weeks before until 12 weeks after start of study therapy (sacubitril/valsartan or enalapril).

NCT ID: NCT02826603 Active, not recruiting - Plaque Psoriasis Clinical Trials

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Start date: June 22, 2016
Phase: Phase 3
Study type: Interventional

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

NCT ID: NCT02825134 Recruiting - Clinical trials for Cardiovascular Diseases

Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis

Start date: June 2016
Phase: N/A
Study type: Interventional

A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic valve replacement in patients 75 years of age or younger suffering from severe aortic valve stenosis. Study hypothesis: The clinical outcome (composite endpoint of all-cause mortality, MI and stroke) obtained within 1 year after TAVR is non-inferior to SAVR.

NCT ID: NCT02780297 Recruiting - Hyperoxaluria Clinical Trials

Prospective Research Rare Kidney Stones (ProRKS)

Start date: May 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

NCT ID: NCT02752633 Completed - Clinical trials for Adenine Phosphoribosyltransferase Deficiency

Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Start date: May 2013
Phase: Phase 4
Study type: Interventional

This exploratory pilot study was an open-label, crossover, single-center and non-randomized clinical trial designed to compare the effect of the standardly employed doses of allopurinol (400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion in patients with adenine phosphoribosyltransferase (APRT) deficiency.

NCT ID: NCT02748863 Active, not recruiting - Psoriasis Clinical Trials

Study of Secukinumab With 2 mL Pre-filled Syringes

Start date: December 3, 2016
Phase: Phase 3
Study type: Interventional

The aim of the study is to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.